H.R. 1254 (112th): Synthetic Drug Control Act of 2011

112th Congress, 2011–2013. Text as of Dec 08, 2011 (Referred to Senate Committee).

Status & Summary | PDF | Source: GPO

IIB

112th CONGRESS

1st Session

H. R. 1254

IN THE SENATE OF THE UNITED STATES

December 8, 2011

Received; read twice and referred to the Committee on the Judiciary

AN ACT

To amend the Controlled Substances Act to place synthetic drugs in Schedule I.

1.

Short title

This Act may be cited as the Synthetic Drug Control Act of 2011.

2.

Addition of synthetic drugs to schedule I of the Controlled Substances Act

(a)

Cannabimimetic agents

Schedule I, as set forth in section 202(c) of the Controlled Substances Act (21 U.S.C. 812(c)) is amended by adding at the end the following:

(d)
(1)

Unless specifically exempted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of cannabimimetic agents, or which contains their salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation.

(2)

In paragraph (1):

(A)

The term cannabimimetic agents means any substance that is a cannabinoid receptor type 1 (CB1 receptor) agonist as demonstrated by binding studies and functional assays within any of the following structural classes:

(i)

2-(3-hydroxycyclohexyl)phenol with substitution at the 5-position of the phenolic ring by alkyl or alkenyl, whether or not substituted on the cyclohexyl ring to any extent.

(ii)

3-(1-naphthoyl)indole or 3-(1-naphthylmethane)indole by substitution at the nitrogen atom of the indole ring, whether or not further substituted on the indole ring to any extent, whether or not substituted on the naphthoyl or naphthyl ring to any extent.

(iii)

3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring, whether or not further substituted in the pyrrole ring to any extent, whether or not substituted on the naphthoyl ring to any extent.

(iv)

1-(1-naphthylmethylene)indene by substitution of the 3-position of the indene ring, whether or not further substituted in the indene ring to any extent, whether or not substituted on the naphthyl ring to any extent.

(v)

3-phenylacetylindole or 3-benzoylindole by substitution at the nitrogen atom of the indole ring, whether or not further substituted in the indole ring to any extent, whether or not substituted on the phenyl ring to any extent.

(B)

Such term includes—

(i)

5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP–47,497);

(ii)

5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (cannabicyclohexanol or CP–47,497 C8-homolog);

(iii)

1-pentyl-3-(1-naphthoyl)indole (JWH–018 and AM678);

(iv)

1-butyl-3-(1-naphthoyl)indole (JWH–073);

(v)

1-hexyl-3-(1-naphthoyl)indole (JWH–019);

(vi)

1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH–200);

(vii)

1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH–250);

(viii)

1-pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH–081);

(ix)

1-pentyl-3-(4-methyl-1-naphthoyl)indole (JWH–122);

(x)

1-pentyl-3-(4-chloro-1-naphthoyl)indole (JWH–398);

(xi)

1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM2201);

(xii)

1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM694);

(xiii)

1-pentyl-3-[(4-methoxy)-benzoyl]indole (SR–19 and RCS–4);

(xiv)

1-cyclohexylethyl-3-(2-methoxyphenylacetyl)indole (SR–18 and RCS–8); and

(xv)

1-pentyl-3-(2-chlorophenylacetyl)indole (JWH–203).

.

(b)

Other drugs

Schedule I of section 202(c) of the Controlled Substances Act (21 U.S.C. 812(c)) is amended in subsection (c) by adding at the end the following:

(18)

4-methylmethcathinone (Mephedrone).

(19)

3,4-methylenedioxypyrovalerone (MDPV).

(20)

3,4-methylenedioxymethcathinone (methylone).

(21)

Naphthylpyrovalerone (naphyrone).

(22)

4-fluoromethcathinone (flephedrone).

(23)

4-methoxymethcathinone (methedrone; Bk–PMMA).

(24)

Ethcathinone (N-Ethylcathinone).

(25)

3,4-methylenedioxyethcathinone (ethylone).

(26)

Beta-keto-N-methyl-3,4-benzodioxyolybutanamine (butylone).

(27)

N,N-dimethylcathinone (metamfepramone).

(28)

Alpha-pyrrolidinopropiophenone (alpha-PPP).

(29)

4-methoxy-alpha-pyrrolidinopropiophenone (MOPPP).

(30)

3,4-methylenedioxy-alphapyrrolidinopropiophenone (MDPPP).

(31)

Alpha-pyrrolidinovalerophenone (alpha-PVP).

(32)

6,7-dihydro-5H-indeno-(5,6-d)-1,3-dioxol-6-amine) (MDAI).

(33)

3-fluoromethcathinone.

(34)

4’-Methyl-α-pyrrolidinobutiophenone (MPBP).

(35)

2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C–E).

(36)

2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C–D).

(37)

2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C–C).

(38)

2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C–I).

(39)

2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C–T–2).

(40)

2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C–T–4).

(41)

2-(2,5-Dimethoxyphenyl)ethanamine (2C–H).

(42)

2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C–N).

(43)

2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C–P).

.

3.

Temporary scheduling to avoid imminent hazards to public safety expansion

Section 201(h)(2) of the Controlled Substances Act (21 U.S.C. 811(h)(2)) is amended—

(1)

by striking one year and inserting 2 years; and

(2)

by striking six months and inserting 1 year.

Passed the House of Representatives December 8, 2011.

Karen L. Haas,

Clerk.